Published Date: 18 Feb 2023
Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis
Read Full NewsSanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.
Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.
Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.
This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.
Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles
Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis
Older Patients on Maintenance Dialysis Underrepresented in RCTs
1.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
2.
Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.
3.
Significant differences in breast cancer care still exist, but surgeons can change.
4.
A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll
5.
Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria
1.
Stomach Cancer: Uncovering the Subtle Signs and Symptoms
2.
Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells
3.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
4.
Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells
5.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
2.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
3.
Navigating the Complexities of Ph Negative ALL - Part II
4.
Navigating the Complexities of Ph Negative ALL - Part XII
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation